Keywords: onyx/bayer, nexavar, gains, ec, orphan, status, german

Onyx/Bayer's Nexavar gains EC Orphan Status

Article | 24 April 2006

German drugmaker Bayer and USA-based Onyx Pharmaceuticals says their co-developed anticancer agent Nexavar (sorafenib) has been granted Orphan Drug status ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Bayer

Go to company listing

Related Drugs

Nexavar

Sorafenib

Aspirin

Bayer

Go to drug listing